Business Standard

Torrent Pharma tumbles 14% on disappointing Q3 results

In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in the US.

Torrent Pharma seeks shareholder nod to raise Rs 10,500 cr
Premium

SI Reporter Mumbai
Shares of Torrent Pharmaceuticals were down 14 per cent to Rs 2,705 on the BSE in Thursday’s intraday trade after the company reported disappointing December quarter (Q3FY22) results on the margins front. Profit after tax (PAT) declined 16 per cent year on year (YoY) to Rs 249 crore.

In Q3FY22, earnings before interest tax and depreciation and amortization (EBITDA) margins declined 490 bps YoY to 25.5 per cent driven by price erosion in US. The management said due to the prolonged delays in reinspection of US facilities on account of the pandemic, coupled with higher than anticipated pricing pressure,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in